Allergan set to make headway in crowded CGRP migraine market, as the battle for formulary coverage begins
Millions of migraine sufferers could soon get their hands on an oral CGRP drug designed to be used as-needed, as Allergan $AGN on Wednesday said it was on track to file for FDA approval for ubrogepant in the first quarter of next year. The multi-billion dollar migraine market is already replete with injectable medications from Teva $TEVA, Eli Lilly $LLY, and one from Amgen $AMGN and Novartis $NVS, which are all designed to be used as preventative treatments and are curiously priced identically.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.